Today: 26 March 2026
Ondas Stock Price: ONDS Slides as $375 Million 2026 Revenue Target, World View Deal Raise Stakes
26 March 2026
2 mins read

Ondas Stock Price: ONDS Slides as $375 Million 2026 Revenue Target, World View Deal Raise Stakes

NEW YORK, March 26, 2026, 08:04 EDT.

  • Ondas closed at $10.31 on Wednesday, March 25, dropping 3.46% as it surrendered some of the ground won during Monday, March 23’s 8.35% surge. Investing.com
  • Management bumped up its 2026 revenue goal, now aiming for a minimum of $375 million, and put out first-quarter guidance calling for $38 million to $40 million in revenue. Investing.com
  • Ondas’ planned purchase of World View comes in at a $150 million price tag, according to a March 23 filing. Most of that consideration? Stock. The deal, if things go as planned, should wrap up in the second quarter.

Ondas Inc dropped 3.5% to $10.31 on Wednesday, giving up more ground after its earlier post-earnings spike. The slide comes as investors look past the upbeat quarter, focusing instead on management’s aggressive deal streak—five acquisitions in Q1, World View among them—and a sharply higher 2026 sales goal. Investing.com

Why does it matter? Ondas is now pitching a bold move to investors. After pulling in $50.7 million in revenue in 2025, the company expects to hit no less than $375 million next year—a figure that’s more than twice what it told investors back in January. Investing.com

On a call with analysts this Wednesday, Chief Executive Eric Brock pointed to “strong momentum across the business” and said there’s “quite a bit of visibility” supporting the updated target. Ondas expects first-quarter revenue between $38 million and $40 million, with most of the recently acquired revenue expected to ramp up starting in the second quarter and continuing for the rest of the year. Investing.com

Fourth-quarter revenue shot up 629% year over year to $30.1 million, Chief Financial Officer Neil Laird said. Gross margin jumped, hitting 42% compared to 21% a year ago. The quarter closed with a net loss of $101 million, mostly reflecting an $82.2 million non-cash warrant revaluation charge. As of year-end, cash, cash equivalents and restricted cash totaled around $594 million; after the January fundraising, pro forma cash topped $1.5 billion. Investing.com

Ondas is looking to leverage its balance sheet as it pushes into the intelligence, surveillance and reconnaissance, or ISR, space—a sector focused on collecting and analyzing security data across large regions. According to a March 23 filing, the World View transaction has a total value of $150 million, with about $129.5 million of that to be paid in Ondas stock. The deal could close in the second quarter.

World View brings high-altitude sensing into the mix for Ondas, which already has drones, counter-drone tech, and ground robotics on its platform, according to the company. Responding to a question from Needham’s Austin Bohlig about demand tied to conflict, Brock pointed to “more demand, more RFP, more urgency”—with RFP meaning formal customer requests for proposals. Ondas Inc.

The move throws Ondas into an already packed field vying for military drone and counter-drone contracts. Just last week, AeroVironment said it would acquire ESAero for $200 million in cash and stock. Red Cat is chasing military drone deals in the Asia-Pacific, and Kratos has been putting attack drones through their paces with Taiwan’s military. Reuters

Wall Street hasn’t backed away. Needham’s Bohlig kept his Buy call this week, bumping up his price target to $23 from $17. According to summaries from TipRanks and Benzinga, Bohlig pointed to Ondas’ ongoing acquisition push and core business momentum as reasons he thinks the company can top its new revenue target. TipRanks

But trouble isn’t off the table. Laird flagged the warrant mark-to-market line as a continued source of earnings volatility. The World View deal also hinges on shareholder approval and a handful of other closing hurdles. Since most of the acquisition is being paid in stock, dilution worries probably stick around if revenue growth falters. Investing.com

Ondas trades at $10.31, a far cry from its 52-week peak of $15.28. Right now, shares seem suspended between lofty expectations and the company’s next tangible milestone. Investing.com

Stock Market Today

  • Innate Pharma Shares Slide on 55% Revenue Drop, Cash Runway Risks Ahead of Q1 2026 Results
    March 26, 2026, 9:00 AM EDT. Innate Pharma (IPH.PA) faces a sharp 55% decline in Q4 revenue, casting a shadow over its financial health ahead of Q1 results scheduled for 26 March 2026. The biotech's stock opened under pressure at €1.094, below its 50- and 200-day averages, signaling investor concern. With cash runway extending only to the end of Q3 2026, funding challenges loom as the company burns through cash at the current rate. The loss-making firm reports an EPS of -0.55 and a high debt-to-equity ratio of 5.25, raising questions about near-term liquidity. Key trial results, particularly for Monalizumab and Lacutamab, alongside partnership updates with AstraZeneca and Sanofi, remain critical catalysts. Traders should watch cash visibility, cost control, and management commentary closely to gauge Innate Pharma's path forward amidst sector headwinds and valuation pressures.
Terns Pharmaceuticals (TERN) Stock Holds Near Merck’s $53 Offer After $6.7 Billion Buyout
Previous Story

Terns Pharmaceuticals (TERN) Stock Holds Near Merck’s $53 Offer After $6.7 Billion Buyout

Go toTop